Algorae Expands AI Drug Combination Pipeline

• Multi-anchor program extends AOS2 from a single anchor (CBD) to 18 anchor drugs
• AOS2 generated over 9 million in silico synergy predictions
• Over 478,000 synergy predictions identified with more than 6,000 combinations

Algorae Pharmaceuticals Ltd. has expanded its AI drug combination pipeline with the AOS2 multi-anchor program, extending from a single anchor (CBD) to 18 anchor drugs. This program generated over 9 million in silico synergy predictions across drug-drug-cell line combinations, spanning diverse therapeutic areas and mechanisms of action. Preliminary filtering identified over 478,000 synergy predictions, with more than 6,000 combinations demonstrating predicted synergy and biological generalisability. The Company is now curating a shortlist of high-priority candidates for further evaluation, factoring in commercial and intellectual property considerations. These candidates will inform ongoing discussions with the Peter MacCallum Cancer Centre for independent validation.

null

null